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Abstract. Macitentan is a dual endothelin receptor antagonist under phase 3 investigation in pulmonary
arterial hypertension. We investigated the effect of cyclosporine (Cs) and rifampin on the pharmaco-
kinetics of macitentan and its metabolites ACT-132577 and ACT-373898 in healthy male subjects. In
addition, in vitro studies were performed to investigate interactions between macitentan and its active
metabolite ACT-132577 with human organic anion-transporting polypeptides (OATPs). The clinical
study (AC-055-111) was conducted as a two-part, one-sequence, crossover study. Ten subjects in each
part received multiple-dose macitentan followed by multiple-dose co-administration of Cs (part A) or
rifampin (part B). In the presence of Cs, steady-state area under the plasma concentration–time proﬁles
during a dose interval (AUCτ) for macitentan and ACT-373898 increased 10% and 7%, respectively, and
decreased 3% for ACT-132577. Steady-state AUCτ of macitentan and ACT-373898 in the presence of
rifampin decreased 79% and 64%, respectively. For ACT-132577, no relevant difference in AUCτ
between the two treatments was observed. Macitentan co-administered with Cs or rifampin was well
tolerated. The complementary in vitro studies demonstrated no marked differences in uptake rates of
macitentan and ACT-132577 between the wild-type and OATP over-expressing cells over the
concentration range tested. Concomitant treatment with Cs did not have any clinically relevant effect
on the exposure to macitentan or its metabolites, at steady-state. Concomitant treatment with rifampin
reduced signiﬁcantly the exposure to macitentan and its metabolite ACT-373898 at steady-state but did
not affect the exposure to the active metabolite ACT-132577 to a clinically relevant extent.
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INTRODUCTION
Macitentan (ACT-064992) is an orally active, tissue-target-
ing dual endothelin ETA and ETB receptor antagonist (ERA)
under phase 3 investigation in pulmonary arterial hypertension
(1,2).Inhumans,macitentanshowsaslowabsorption;maximum
plasma concentrations are achieved approximately 8 h after
administration.Inadditiontomacitentan,twometabolites,ACT-
132577 (depropylated metabolite) and ACT-373898 (carboxylic
acid metabolite), have been identiﬁed in plasma with ACT-
132577 being pharmacologically active. While the elimination
half-life (t1/2) is approximately 16 h for macitentan, ACT-132577
has a t1/2 of approximately 48 h. ACT-373898 has a similar
pharmacokinetic (PK) proﬁle to macitentan. There are no
notable differences in PK parameters of macitentan and its
active metabolite between malesa n df e m a l e sa n d / o rb e t w e e n
CaucasianandJapanesesubjects(3). Inaddition, macitentan can
be given to subjects irrespective of food intake.
Early phase studies have shown macitentan to have a
good safety and tolerability proﬁle. The most frequently
reported adverse event (AE) is headache (2,4).
Cyclosporine (Cs) and rifampin were used to investigate
the role of metabolism and drug transport in the disposition
of macitentan. The immunosuppressant Cs is an inhibitor of
CYP3A4, the hepatic uptake transporter organic anion-
transporting polypeptide (OATP) (5), and the efﬂux trans-
porter P-glycoprotein (6). Rifampin, an antibiotic mainly used
for the treatment of tuberculosis, is a strong inducer of
CYP3A4 and an effective inhibitor of OATP (7–9). As the
metabolism of macitentan mainly relies on CYP3A4, the
inﬂuence of these two drugs on the PK of macitentan is of
particular interest (10). In addition, drug–drug interactions
(DDIs) at the level of hepatic OATPs have been documented
following co-administration of other structurally related ERAs
and Cs (11,12). As Cs and rifampin may be used concomitantly
with macitentan in clinical practice, we investigated in a two-
part, one-sequence, crossover study the effect of multiple-dose
Cs (part A) and rifampin (part B) on the PK of macitentan and
its metabolites. In addition, in vitro studies were performed to
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metabolite ACT-132577 with human OATP transporters.
MATERIALS AND METHODS
Subjects
It was planned to enroll a total of 20 subjects, 10 in part
A and 10 in part B. Healthy male subjects (based on medical
history and screening examination) aged between 18 and
45 years, with body mass index (BMI) between 18 and
28 kg/m
2, were eligible for this study. In addition, eligible
subjects had to have hematology and clinical chemistry
results within the normal range and negative results for
drug and alcohol use at screening. Subjects were excluded
from the study if they had received any drug with
immunosuppressive potential within 6 months preceding
the screening examination or if they were administered
any metabolic enzyme-inducing or enzyme-inhibiting drugs
within the last 4 weeks prior to the screening examination.
The ethics committee, Comité de Protection des Personnes
Ouest VI, located in Brest (France), approved the study
protocol (study number AC-055-111), and all subjects gave
written informed consent before any screening procedures were
performed. The study was conducted in full conformity with the
principles of the Declaration of Helsinki, the EMEA Note for
Guidance on Good Clinical Practice (CPMP/ICH/135/95), and
International Ethical Guidelines for Biomedical Research
Involving Human Subjects (Council for International Organ-
izations of Medical Sciences 2002).
Clinical Study Design
This phase 1, single-center, open-label, two-part, one-
sequence crossover study consisted of two parts. Each part
comprised two periods: period 1, multiple-dose treatment
with macitentan, and period 2, multiple-dose treatment with
macitentan and Cs (part A) or multiple-dose treatment with
macitentan and rifampin (part B).
An oral dose of 10 mg macitentan once daily was assessed
in this study, which corresponds to the maximum dose used in
the ongoing phase 3 program. The use of a 30-mg loading dose
on day 1 reduced the time to reach steady-state conditions of
ACT-132577 (day 4 instead of day 7). In the single-ascending
dose study, doses of up to 300 mg had been well tolerated (2). In
part A, after 5 days administration of macitentan, subjects were
co-administered oral doses of 100 mg of Cs (1×100 mg capsule
of Neoral
®) every 12 h on days 6 through 17. The dose of 2×
100 mg/day of Cs used in this study corresponds to
approximately 2.9 mg/kg/day for a 70-kg man. This is within
therecommended range fortransplantation indications,i.e.,2 to
6 mg/kg/day, and is below the dose level of 5 mg/kg/day known
to potentially increase creatinine and hypertension side effects
(13). Both drugs were administered after food.
In part B, after 5 days administration of macitentan, oral
doses of 600 mg rifampin (two capsules of 300 mg Rifadin
®)
were co-administered once daily for 7 days, on days 6 through
12. This dosing regimen is approved for the treatment of
tuberculosis and is recommended by the Food and Drug
Administration (FDA) for assessment of its enzyme-inducing
effect (14,15). Since food intake has a signiﬁcant effect on the
PK of rifampin, drugs were administered under fasted
conditions (1 h before a meal).
An End of Study examination, including vital signs,
electrocardiogram (ECG), and clinical laboratory tests, took
place 2 weeks after the last PK blood sampling, i.e., on day 32
(±2 days) of part A and on day 27 (±2 days) of part B. A
telephone safety follow-up for serious adverse events (SAEs)
took place 30 days after the last study drug administration.
Trough concentrations of macitentan and its metabolites
were determined in blood samples taken from days 1 to 17
(part A) and from days 1 to 12 (part B) prior to daily
macitentan administration. Twenty-four-hour concentration–
time proﬁles of macitentan and its metabolites on day 5 (96–
120 h) and day 17 (384–408 h) (part A) or day 12 (264–288 h)
(part B) were determined in blood samples drawn immediately
before and at 1, 3,5, 6, 7,8, 9, 10, 11,12, 13, 14, 16, and24 h after
macitentan administration.
For each time point, approximately 3 mL of blood was
collected from the subject in tubes containing ethylene
diamine tetra-acetic acid. Within 30 min after collection, the
tubes were centrifuged at approximately 1,500×g for 10 min at
2°C to 8°C. The plasma was stored at −20°C until analysis.
Bioanalytical Methods and PK Assessments
Quantiﬁcation of macitentan, ACT-132577, and ACT-
373898 in plasma was performed by a validated liquid
chromatography with tandem mass spectrometry (LCMS/
MS) method. Analytes were extracted from plasma by
protein precipitation with ethanol (EtOH)/acetonitrile
(50:50, v/v) containing the internal standards (polydeuterated
analogs of macitentan, ACT-132577, and ACT-373898) and
ﬁltered through a protein precipitation plate (0.2 μm pore
size), before injection into the high performance liquid
chromatography system. The samples were subsequently
analyzed by triple-stage quadrupole tandem mass spectrom-
etry (MS/MS). The concentrations of the analytes were
determined using the internal standardization method. The
square of the correlation coefﬁcient (R
2) was at least 0.9985
for macitentan, 0.9863 for ACT-132577, and 0.9932 for ACT-
373898 in all runs. For macitentan, the inter-day precision
(coefﬁcient of variation) of control samples was ≤8.6%,
and inter-day inaccuracy ranged from −4.3% to 5.3%. For
ACT-132577, inter-day precision was ≤7.0%, and inter-day
inaccuracy ranged from −5.7% to −2.0%. For ACT-
373898, inter-day precision was ≤10.1%, and inter-day
inaccuracy was in therangeof−9.3%to 1.8%.Thelower limit
of quantiﬁcation (LLOQ) was 1 ng/mL for macitentan and
ACT-132577, and 0.5 ng/mL for ACT-373898.
The measured individual plasma concentrations of maci-
tentan, ACT-132577, and ACT-373898 were used to calculate
PK parameters by model-independent analysis, using the
WinNonlin 6.1 or Phoenix software packages (Pharsight
Corporation, Mountain View, CA, USA). The measured
individual plasma concentrations immediately before the
morning dose of macitentan were used to directly obtain
trough concentrations (Ctr). The area under the plasma
concentration–time curve (AUC) was calculated according to
the linear trapezoidal rule, using the measured concentration–
time values above the LLOQ.
69 Cs, Rifampin, Macitentan PharmacokineticsSafety Assessments
Tolerability and safety were evaluated by recording SAEs,
AEs, clinical laboratory variables, vital signs, and 12-lead ECG
during the study.
Statistical Analysis
The effect of Cs and rifampin on the steady-state area
under the plasma concentration time curve during a dose
interval (AUCτ) and Ctr of macitentan and its metabolites
were explored using the ratio of geometric means and its 90%
conﬁdence intervals of macitentan + Cs (or macitentan +
rifampin) versus macitentan. Tolerability and safety endpoints
were analyzed descriptively.
In Vitro Experiments
Chinese Hamster Ovary Cell Culture
Wild-type and Chinese hamster ovary (CHO) cells over-
expressing OATP1B1 and OATP1B3 were maintained in
Dulbecco's modiﬁed eagle's medium supplemented with 10%
(v/v) fetal calf serum, penicillin/streptomycin (100 IU/mL),
and L-proline (0.05 mg/mL) at 37°C in a humidiﬁed atmo-
sphere containing 5% CO2. The culture medium for trans-
fected cells also contained geneticin (500 μg/mL). For
transport experiments, cells were seeded 1:10 or 1:20
on 8-cm
2 tissue culture dishes (Vitaris, Zug, Switzerland)
3 to 4 days before assaying. One day before the experiments,
5μM sodium butyrate (Sigma–Aldrich,Buchs,Switzerland)was
also added.
Transport Experiments
Transport experiments with wild-type and transfected
CHO cells were performed in parallel using two to three
8-cm
2 tissue culture dishes for each concentration. After
washing the cells three times with a pre-warmed (37°C) buffer
(5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-
glucose, 20 mM HEPES, 116.4 mM NaCl, pH 7.4 at room
temperature), uptake of a test compound was initiated by
adding 1 mL of the same buffer containing the test compound
at desired concentration (as
14C-labeled alone or as a mixture
with non-labeled test compound). The ﬁnal concentration of
organic solvent was 1% (v/v). Uptake of a test compound was
stopped after incubation at 37°C for the desired duration by
twice adding 2-mL aliquots of ice-cold buffer containing 0.5%
(w/v) bovine serum albumin (BSA) (Sigma, Buchs,
Switzerland). Cells were then rapidly washed four times
with approximately 2 mL of ice-cold buffer and solubilized
by the addition of 1 mL of 1% (w/v) Triton X-100. After
incubation for at least 20 min, cell lysate (0.5 mL) was mixed
with 5 mL of scintillation cocktail IRGA Safe Plus
(PerkinElmer, Zurich, Switzerland), and radioactivity was
determined using a Tri-Carb 2300 TR liquid scintillation
analyzer (Packard Bioscience, Zurich, Switzerland). Aliquots
of cell lysates (25 μL) were used to determine the protein
content of each sample using the Pierce BCA (bicinchoninic
acid) assay (Pierce Science, Lausanne, Switzerland) according
to the supplier's protocol. BSA was used as standard.
The inhibitory potential of macitentan and ACT-132577 on
the cellular uptake of prototypical OATP substrates was investi-
gated at a single substrate concentration (≤Km)o f1μM
atorvastatin for OATP1B1 and 5 μM estrone-3-sulfate for
OATP1B3. After incubation at 37°C for 40 s (OATP1B1) and
90 s (OATP1B3), the uptake was terminated by twice adding 2 mL
of ice-cold buffer containing 0.5% (w/v) BSA. Afterwards, sample
preparation and analysis were performed as outlined above.
Data Evaluation
In order to determine uptake rates, cellular uptakes were
normalized to total protein content and incubation time. Net
OATP-mediated uptake rates were calculated as the differ-
ence in the uptake rates of the transfected and wild-type cells
for each individual concentration. Half maximal inhibitory
concentration (IC50) values for uptake inhibition were
determined by plotting the inhibitor concentration (logarith-
mic scale) against the net uptake rates and nonlinear
regression using the equation:
y ¼
Top
1 þ x
IC50
 s þ Bottom
where y is the net uptake rate (picomoles per milligram protein
per minute), x is the inhibitor concentration (micromolars), s is
the slope at the point of inversion, and Top and Bottom are the
maximum and minimum values for cellular uptake rates,
respectively. For all graphical data evaluations, the GraphPad
Prism software package (version 5.0, GraphPad Software Inc.,
La Jolla, CA) was used. The ﬁtted parameters are presented as
best-ﬁt parameter and standard error (SE).
RESULTS
Demographics and Baseline Characteristics
Ten healthy male subjects in part A (age±standard
deviation [SD], 29±9 years; BMI±SD, 22.1±2.8 kg/m
2) and
10 healthy male subjects in part B (age±SD, 33±10 years;
BMI±SD, 23.0±1.5 kg/m
2) were enrolled. All subjects were
Caucasian. All completed the study as per protocol. None of
the subjects (in parts A and B) were exposed to any
prescribed or over-the-counter drug (including herbal
medicines) for 3 months prior to screening.
Pharmacokinetics
Part A. Mean concentration–time proﬁles of macitentan,
ACT-132577, and ACT-373898 in period 1 (multiple-dose
macitentan treatment) followed by period 2 (multiple-dose
co-administration of Cs) are shown in Fig. 1. In period 1,
plasma concentrations of macitentan, ACT-132577, and ACT-
373898 approached steady-stateonday5 (96 h)ofdosing.Inthe
presence of Cs (period 2), no relevant changes in Ctr of
macitentan and its metabolites were observed compared to
macitentan treatment alone. The mean 24-h plasma concentra-
tion–timeproﬁlesatsteady-stateinthetwoperiods,i.e.,onday5
(period 1) and day 17 (period 2), for macitentan and its
metabolites were similar (Fig. 2).
70 Bruderer et al.Fig. 1. Part A: Arithmetic mean ± SD plasma concentration versus time proﬁles of macitentan, ACT-
132577, and ACT-373898 from days 1 to 17. The last day of treatment with macitentan in period 1 (day 5)
and last day of treatment with macitentan+Cs in period 2 (day 17) are indicated in the ﬁgure
Fig. 2. Part A: Arithmetic mean ± SD plasma concentration versus time proﬁles of macitentan, ACT-
132577, and ACT-373898 on day 5 (period 1: macitentan) compared to day 17 (period 2: macitentan+Cs)
71 Cs, Rifampin, Macitentan PharmacokineticsGeometric means of steady-state AUCτ for macitentan,
ACT-132577, and ACT-373898 in the absence of Cs treatment
were 6,876, 16,881, and 530 ng·h/mL, respectively, compared to
7,562, 16,428, and 568 ng·h/mL in the presence of Cs (Table I).
The comparison of geometric means of PKvariables inpartA is
shown in Table II. The ratio of geometric means and their 90%
conﬁdence limits of AUCτ for ACT-132577 fell entirely within
the FDA-recommended bioequivalence range of 0.80–1.25,
whereas for macitentan and ACT-373898, at least one of the
conﬁdence limits were outside of this range (Table II)( 15).
Part B. Mean concentration–time proﬁles of macitentan
and its metabolites ACT-132577 and ACT-373898 in period 1
(multiple-dose macitentan treatment) followed by period 2
(multiple-dose co-administration of rifampin) are shown in
Fig. 3. Steady-state conditions were approximately attained
on day 5 (96 h) of dosing in the absence of rifampin. In the
presence of rifampin treatment, Ctr of macitentan decreased
from days 6 to 12, and new steady-state conditions were
approached on day 12 (264 h). A similar situation was
observed for ACT-373898. The start of concomitant treat-
ment of rifampin on day 6 caused an initial increase in Ctr of
ACT-132577, which gradually decreased with continued
dosing and approached steady-state concentrations on
day 12 (264 h) which were similar to the original steady-state
concentrations. The comparison of 24-h plasma concentra-
tion–time proﬁles at steady-state in the two periods, i.e., on
days 5 and 12, showed that concentrations of macitentan and
ACT-373898 on day 12 were considerably lower than those
on day 5 (Fig. 4). The differences in concentrations of ACT-
132577 between days 5 and 12 were much smaller compared
to those of macitentan and ACT-373898.
Geometric means of steady-state AUCτ for macitentan,
ACT-132577, and ACT-373898 from periods 1 to 2 decreased
from 5,775 to 1,240 (a 79% decrease), 14,846 to 14,798 (a
0.3% decrease), and 484 to 176 ng·h/mL (a 64% decrease),
respectively (Table I). The ratio of geometric means and their
90% conﬁdence limits of AUCτ for ACT-132577 fell entirely
within the FDA-recommended bioequivalence range of 0.80–
1.25, whereas for macitentan and ACT-373898, they were
completely outside of this range (Table II).
Tolerability and Safety
There were no deaths, SAEs, or AEs leading to
treatment discontinuation. None of the AEs led to a
withdrawal or any change in the conduct of the study. All
AEs were of mild or moderate severity and were resolved at
the end of the study with no sequelae.
In part A of the study, a total of 12 treatment-emergent
AEs (TEAEs) occurred, of which three occurred during
period 1, affecting three subjects (30%), and nine affecting six
subjects (60%) occurred during period 2. The most frequently
reported TEAE was headache, which affected one subject in
period 1 and three subjects in period 2.
In part B of the study, a total of eight TEAEs occurred,
of which six occurred during period 1, affecting six subjects
(60%), and two affecting two subjects (20%) occurred during
period 2. The most frequently reported TEAE was headache,
which affected ﬁve subjects in period 1 and two subjects in
period 2.
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72 Bruderer et al.No clinically relevant treatment-related effects on vital
signs, ECG variables, or clinical laboratory variables were
detected in either part of the study.
In Vitro Experiments
To assess whether macitentan and its active metabolite
ACT-132577 are substrates of human OATPs, time- and
concentration-dependenceassessmentswereperformedinvitro.
Rapid and comparable uptake of macitentan and ACT-132577
was observed in wild-type and OATP1B1 as well as OATP1B3
over-expressing CHO cells (Fig. 5). The uptake of macitentan
into the wild-type, OATP1B1, and OATP1B3 over-expressing
cells after incubation for 40 s was (mean ± SD) 346±3, 362±6,
and 387±11 pmol/mg, respectively, and the uptake of ACT-
132577 was 214±11, 237±7, and 288±10 pmol/mg, respectively.
No marked difference in uptake rate of macitentan and ACT-
132577 between wild-type and OATP over-expressing cells was
Table II. Ratios of geometric means of steady-state AUCτ and Ctr of macitentan and its metabolites in the presence of cyclosporine or
rifampin treatment (period 2) versus macitentan treatment alone (period 1)
Statistics
Part A Part B
Macitentan+Cs vs macitentan Macitentan+rifampin vs macitentan
AUCτ (ng·h/mL) Ctr (ng·h/mL) AUCτ (ng·h/mL) Ctr (ng·h/mL)
Macitentan Ratio of geometric means 1.10
a 1.38
a 0.21
a 0.07
a
90% conﬁdence interval 0.91–1.33 1.06–1.81 0.17–0.26 0.05–0.10
ACT-132577 Ratio of geometric means 0.97 1.02 1.00 0.83
a
90% conﬁdence interval 0.85–1.11 0.87–1.19 0.89–1.12 0.73–0.94
ACT-373898 Ratio of geometric means 1.07
a 1.12
a 0.36
a 0.14
a
90% conﬁdence interval 0.79–1.45 0.81–1.55 0.27–0.50 0.09–0.20
Part A: Ratio of geometric mean of AUCτ in Period 2 versus Period 1: AUC(384h - 408h)/AUC(96h - 120h). Ratio of geometric mean of Ctr in
Period 2 versus Period 1. Part B: Ratio of geometric mean of AUCτ in Period 2 versus Period 1: AUC(264h - 288h)/AUC(96h - 120h). Ratio of
geometric mean of Ctr in Period 2 versus Period 1
aRatio of geometric means and 90% conﬁdence intervals where at least one of the conﬁdence limits falls outside the FDA-accepted
bioequivalence range of 0.80–1.25
Fig. 3. Part B: Arithmetic mean ± SD plasma concentration versus time proﬁles of macitentan, ACT-
132577, and ACT-373898 from days 1 to 12. The last day of treatment with macitentan in period 1 (day 5)
and last day of treatment with macitentan+rifampin in period 2 (day 12) are indicated in the ﬁgure
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(Fig. 6).
The inhibitory potential of macitentan and ACT-132577 on
OATPs was investigated over a wide range of inhibitor
concentrations (0.01 to 300 μM). Macitentan inhibited
OATP1B1-mediated uptake of atorvastatin and OATP1B3-
mediated uptake of estrone-3-sulfate with IC50±SE values of
6.3±0.7 and 11.8±5.0 μM, respectively (Fig. 7). For ACT-
132577, these values were 19.9±1.4 and 51.6±3.0 μM, respec-
tively (Fig. 7).
DISCUSSION
The clinical study was conducted in two parts. In both
parts, Ctr of macitentan and its metabolites were comparable
in the absence of Cs or rifampin, and they were consistent
with previous results (16).
Part A. It has been shown that Cs may affect the PK of
numerous compounds through its inhibitory effect on
CYP3A4 or OATP transporters (11,12,17–19). The results of
a previously performed study investigating the interaction
between macitentan and ketoconazole, a strong CYP3A4
inhibitor, showed a small effect of ketoconazole on the
exposure to macitentan (approximately two-fold increase of
the area under the plasma concentration–time curve from
zero to inﬁnity [AUC0–∞]), which was not considered
clinically relevant (10). Since Cs is a weaker CYP3A4
inhibitor than ketoconazole, a large effect of Cs on the
exposure to macitentan through CYP3A4 inhibition was
not expected. However, in this study, the investigation of
a potential increase in exposure to macitentan through
inhibition of OATP transporters by Cs was of greater
interest. The results showed that in the presence of Cs,
the exposure to macitentan and its metabolites did not
change to a clinically relevant extent, which indicates no
signiﬁcant interaction between these two drugs at the level
of metabolizing enzymes and/or transporters such as
OATP.
This ﬁnding is different from that reported for other
ERAs, such as ambrisentan or bosentan, which showed
OATP involvement in the interaction of those ERAs with
Cs (11,12,19). The signiﬁcant initial increase in exposure
to bosentan seen in the presence of Cs in humans (a 30-
fold increase after the ﬁrst day of co-administration of Cs)
was attributed not only to the inhibition of metabolizing
enzymes but mainly to the inhibition of OATP by Cs and
consequently reduced hepatic uptake (17). Cs may be
used concomitantly with pulmonary arterial hypertension
therapies, particularly in those patients with connective
tissue disease. In addition, calcineurin inhibitors, including
Cs, are used to prevent host organ rejection during solid
organ transplantation procedures. However, calcineurin
inhibitors can limit the success of kidney transplantation
due to calcineurin inhibitor-mediated nephrotoxicity. Data
from previous studies suggest that some ERAs may
attenuate Cs toxicity and may be useful in solid organ
transplantation studies (20–22); in contrast to other ERAs,
macitentan does not show any interaction with Cs either
at the level of CYP enzymes or at the level of OATP
transporters. Therefore, macitentan in combination with
Fig. 4. Part B: Arithmetic mean ± SD plasma concentration versus time proﬁles of macitentan, ACT-132577,
and ACT-373898 on day 5 (period 1: macitentan) compared to day 12 (period 2: macitentan+rifampin)
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without the need for macitentan dose adjustment.
Part B. In the presence of rifampin, exposure to
macitentan decreased markedly. This indicates that the
metabolism of macitentan is induced in the presence of
rifampin, a strong inducer of CYP3A4. Complex interactions
have been observed between rifampin and a number of drugs,
including ERAs, which are subject to both CYP3A4-mediat-
ed oxidation and OATP-mediated hepatic uptake. These
studies have typically revealed a biphasic response character-
ized by an initial, transient increase in ERA plasma concen-
tration with acute rifampin administration, presumably due to
OATP inhibition, followed by reduction in exposure attribut-
ed to CYP3A4 induction (23–26). Such biphasic effects of
rifampin are not observed with macitentan, which further
demonstrates the absence of a contribution from OATP to
the disposition of macitentan. The initial increase seen in
trough concentrations of ACT-132577 after the ﬁrst doses of
rifampin could be explained by an increase in macitentan
metabolism at the level of CYP3A4, resulting in an increased
transformation rate to ACT-132577. Rifampin has also been
reported to be an inducer of conjugation enzymes, which
render drugs more polar and facilitate their excretion (7). In
humans, conjugation enzymes are involved in the elimination
of ACT-132577, which could in turn be induced by rifampin,
accelerating the elimination of ACT-132577. This hypothesis
is supported by the observation that the exposure to ACT-
132577 after continued dosing (day 12) was very similar to
that without rifampin. OATP is unlikely to be involved in the
initial increase of exposure to ACT-132577 based on the fact
that concomitant treatment with Cs, also a major inhibitor of
OATP, did not show the same effect. Since both rifampin and
macitentan would be administered on a multiple-dose basis if
used together, the exposure at steady-state (day 5 compared
to day 12) is considered to be the most relevant comparison
between the two treatment conditions.
Macitentan and its metabolite ACT-132577 are both
potent dual ERAs, and both contribute to the overall
pharmacological effect of macitentan in vivo. ACT-132577 is
approximately ﬁve-fold less potent than macitentan in vitro.
However, systemic exposure in humans to ACT-132577 is 2.5-
fold higher than to macitentan. Although the exposure to
ACT-132577 at steady-state was not affected by concomitant
treatment with rifampin, the approximately four-fold reduc-
tion in exposure to macitentan in the presence of rifampin
might affect the overall pharmacological effect of the drug.
Thus, reduced efﬁcacy of macitentan in the presence of
concomitant treatment with rifampin should be considered.
The results from in vitro OATP studies support the
observations from the clinical study. High cellular uptake
rates of macitentan and ACT-132577 in wild-type cells as well
as OATP over-expressing CHO cells suggest that their
cellular uptake does not depend on human OATP trans-
porters but is likely to be driven by passive diffusion. A small
contribution from active uptake could not be totally excluded,
however, although compared to the high passive component,
it is considered not to be relevant. The present in vitro data
give a possible mechanistic explanation why the concom-
itant administration of the potent OATP inhibitor Cs did
not increase the exposure to macitentan and ACT-132577
to a clinically relevant extent and explain why Ctr of
macitentan did not show any immediate increase in the
presence of rifampin.
The question whether macitentan and its active metab-
olite ACT-132577 could act as a perpetrator in DDIs was also
assessed in in vitro studies. Macitentan and ACT-132577
exhibited an inhibitory potency on OATP1B1-mediated
uptake of atorvastatin, as well as OATP1B3-mediated uptake
of estrone-3-sulfate. Comparing the IC50 values and total
plasma concentrations of macitentan and ACT-132577 at
steady-state in healthy subjects (approximately 0.63 and
1.5 μM, respectively) during a 10-mg once-daily regimen
and binding of macitentan and ACT-132577 to human plasma
proteins in vitro (99.6% and 99.5%, respectively) indicates
that the free steady-state concentration of macitentan and
ACT-132577 is around 2.5 and 7.3 nM, respectively. Since free
steady-statemacitentanandACT-132577plasmaconcentrations
are around 2,490-fold lower than the lowest IC50 determined, it
appears unlikely that treatment with macitentan will affect the
PK of co-administered OATP substrates.
Based on the guidance for industry issued in 2008 by the
Center for Drug Evaluation and Research, ACT-373898,
identiﬁed in the human absorption, distribution, metabolism,
and excretion study, was considered as a second major
Fig. 5. Time course of cellular uptake of 3 μM macitentan (a) and
3 μM ACT-132577 (b) in wild-type (circles) and human OATP1B1
(squares)a n dO A T P 1 B 3( triangles) over-expressing CHO cells.
Values represent the mean±SD of one experiment performed in
triplicate
75 Cs, Rifampin, Macitentan PharmacokineticsFig. 7. Concentration-dependent inhibition of OATP1B1-mediated net uptake of atorvastatin (a, c) and OATP1B3-
mediated uptake of estrone-3-sulfate (b, d) by macitentan and ACT-132577. Values represent the mean±SD of one
experiment done in triplicate, and the solid line is best ﬁt to the data
Fig. 6. Concentration dependence of cellular uptake of macitentan (panels a and b) and ACT-132577 (panels c and d)i n
wild-type (circles) and human OATP1B1 (a, c) and OATP1B3 (b, d), over-expressing CHO cells (squares). Values represent
the mean±SD of one experiment performed in triplicate
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was also analyzed in the present study. However, in view of
the more recently issued guidance by the International
Conference on Harmonization in 2010 (29), ACT-373898 is
no longer considered a major metabolite.
Similar to previous phase 1 studies with macitentan, the
most frequent TEAE was headache (2,4,10). In part A, no
hypertension or AEs relating to renal function, which are
associated with Cs treatment, were reported (13). Similarly in
part B, no AEs associated with rifampin treatment were
reported (14). Overall, tolerability of macitentan when
administered concomitantly with Cs or rifampin was good.
However, the small number of subjects limits the inter-
pretation of safety data in both parts of the study, and
more data in a larger patient population are necessary to
evaluate adequately the safety of macitentan in combina-
tion with Cs and rifampin.
CONCLUSION
The observed effect of Cs on the exposure to macitentan
and its metabolites ACT-132577 and ACT-373898 under
steady-state conditions is not considered clinically relevant.
Concomitant treatment with rifampin reduced signiﬁcantly
the exposure to macitentan and its metabolite ACT-373898 at
steady-state but did not affect the exposure to the active
metabolite ACT-132577 to a clinically relevant extent.
Reduced efﬁcacy of macitentan in the presence of rifampin
should be considered. Hepatic uptake of macitentan and its
active metabolite ACT-132577 does not depend on OATP.
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